Trials / Completed
CompletedNCT01949324
A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Neurotech Pharmaceuticals · Industry
- Sex
- All
- Age
- 21 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase 2, randomized, multi-center, single-masked study to evaluate the efficacy and safety of the NT-501 implants in participants with Mactel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ciliary neurotrophic factor (CNTF) | Ciliary neurotrophic factor released from NT-501 encapsulated cell implant |
| PROCEDURE | Sham procedure | Sham surgery for Sham arm |
| DEVICE | NT-501 Implant | NT-501 encapsulated cell implant |
| PROCEDURE | NT-501 Implant procedure | Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2017-04-14
- Completion
- 2017-05-22
- First posted
- 2013-09-24
- Last updated
- 2018-09-12
Locations
11 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT01949324. Inclusion in this directory is not an endorsement.